Semaglutide brand names include Ozempic, Rybelus, and Wegovy, all made by Novo Nordisk, and Mounjaro from Eli Lilly
The current paradigm to address non-pulmonary vein sources of AFib is to extend the ablation to include more atrial tissue, which has had limited success
Dosage plays a significant role in effectiveness, regardless of the method you choose
Promising safety profile: Early trials report tolerability comparable to incretin-based agents, though higher doses are associated with GI side effects (nausea, diarrhea, vomiting, constipation) Clinical Advantage over Others (Clinical Trial Evidence) Phase 2 obesity studies: At 48 weeks, retatrutide delivered weight reductions up to 24%, far exceeding results reported for monotherapy GLP-1 agents